RUNX2 and breast cancer: miR-302b maintain SOX2 and c-MYC to produce cytokine-induced cancer stem cell-like properties in breast cancer cell co-cultured with immature adipocyte [76]; whilst miR-302b in breast cancer targets RUNX2, an activator of PI3K/AKT signaling [77].